Fisher & Paykel Healthcare (NZX: FPH; ASX: FPH) praised the performance of several new masks to treat obstructive sleep apnea, as the New Zealand-based manufacturer announced record first-half revenue numbers in a Nov. 28 earnings call.
The call discussed Fisher & Paykel’s results for the first half of the 2025 financial year, which ended Sept. 30.
The company reported total operating revenue of $951.2 million, “an increase of 18% from the prior corresponding period or 17% in constant currency,” Fisher & Paykel said in a news announcement after the earnings call. “Net profit after tax for the first half was $153.2 million, up 43% over the same period in the previous financial year.”
New product introductions lead the way
“This result was driven primarily by new product introductions and changing clinical practice,” said Fisher & Paykel Managing Director/CEO Lewis Gradon. “Early indications are that a relatively high hospital census during the period may have contributed as well, as hospitals returned to more normalized staffing and capacity, and seasonal hospitalizations in the northern hemisphere from FY24 [financial year 2024] persisted into the beginning of our current financial year.”
Gradon referenced the introductions of the Nova Micro mask in November, and the earlier launches of the F&P Solo AutoFit mask and F&P Evora Full mask, while discussing Fisher & Paykel’s Homecare product line. “We are also pleased with the continued strong performance of our range of masks for patients with obstructive sleep apnea,” he said on the call. “With the introduction of the F&P Nova Micro mask, alongside our recently launched F&P Solo AutoFit mask and F&P Evora Full, we address a diverse array of patient needs and preferences with our latest technology.”
Gradon added that the company believes the three new masks “will continue to drive similar results for the remainder of the financial year.”
First-half revenue for the Homecare product group was a record $359.4 million, a 14% increase compared to figures from the first half of last year, Fisher & Paykel announced. Specifically, sales of masks and related sleep apnea accessories were up 14%.
Hospital product group first-half revenue was $591.4 million, an increase of 21% from the previous year. The hospital product group includes humidification products for respiratory, acute, and surgical care.
